| Project/Area Number |
18K07993
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 53010:Gastroenterology-related
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2018-04-01 – 2021-03-31
|
| Project Status |
Completed (Fiscal Year 2020)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2019: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2018: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | BRAF / non-coding RNA / miRNA / 発がん / 大腸がん / 治療開発 / 大腸癌 |
|---|
| Outline of Final Research Achievements |
The aim of this study was to clarify the mechanisms underlying carcinogenesis of BRAF-mutated/CIMP-positive colorectal cancer in which certain non-coding RNAs are involved, and to identify novel therapeutical molecular targets involved in the carcinogenesis. We have previously published our research demonstrating that miR-193a-3p acts as a tumor-suppressor in BRAF-mutated cancer. To clarify its more detailed functions, we performed comprehensive miRNA expression analysis, proteome analysis, and some functional assays regarding cellular proliferation, apoptosis, and invasion/metastasis using human colorectal cancer cell lines. As a result, we found that miR-193a-3p acts as a tumor-suppressor and modulated sensitivity by some molecularly-targeted agents in BRAF-mutated cancer (a manuscript is being submitted).
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究で得られた知見から、BRAF変異大腸がんでの新規標的分子の候補をいくつか見出した。現在、それらを標的とした分子標的治療の開発に着手し、臨床開発を目指している。この取り組みがさらに順調に進めば、予後不良のBRAF変異大腸がんでの治療成績向上につながり、大きな社会的意義が期待される。
|
